CesarAugustoSanta-MariaMDMSCI

Oncology • Baltimore, MD

Breast Cancer

Associate Professor of Oncology

Join to view full profile

Dr. Santa-Maria is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Santa-Maria's full profile

Already have an account?

Office
201 North Broadway Street
Viragh BLDG 10th FL
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Summary

Dr. Cesar Santa-Maria is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Sibley Memorial Hospital. He received his medical degree from McGovern Medical School at UTHealth and has been in practice 16 years. He specializes in breast cancer and is experienced in immunotherapy, breast cancer, and clinical research. He has more than 60 publications and over 500 citings.

Education & Training

NorthwesternMSCI, 2015 - 2017
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2008 - 2011
McGovern Medical School at UTHealthClass of 2004

Certifications & Licensure

MD State Medical License 2011 - 2025
DC State Medical License 2019 - 2024
NC State Medical License 2020 - 2022
IL State Medical License 2014 - 2020
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer Start of enrollment: 2018 Nov 13
Active, not recruiting
Phase 2
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer Start of enrollment: 2021 Jul 21
Recruiting
Phase 2
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Recruiting
Phase 2
Roles: Contact, Principal Investigator
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC Start of enrollment: 2024 May 01
Recruiting
Phase 2
Roles: Study Chair, Contact
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Start of enrollment: 2019 Jul 08
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

86 citations
Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study.
Li Juanjuan, Cesar A. Santa-Maria, Feng Hongfang, Wang Ling-cheng, Zhang Pengcheng
Clinical Breast Cancer. 2020-06-07
42 citations
In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
Hanwen Wang, Oleg Milberg, Imke H. Bartelink, Paolo Vicini, Bing Wang
Royal Society Open Science. 2019-05-22
82 citations
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Cesar August Santa-Maria, Taigo Kato, Jae-Hyun Park, Kazuma Kiyotani, Alfred Rademaker
Oncotarget. 2018-04-10

Press Mentions

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer PatientsOctober 31st, 2024
Computational Tool Predicts Immunotherapy Outcomes in Metastatic Triple-Negative Breast CancerOctober 30th, 2024
Computational Tool Developed to Predict Immunotherapy Outcomes for Patients with Metastatic Breast CancerOctober 29th, 2024
Join now to see all

Professional Memberships